Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
[Significance of Mesenchymal Stem Cells in Gastrointestinal Disorders]. [electronic resource] by
- Gamba, S
- Zhao, Y
- Zhao, L
- Wang, Y
- Schwarz, B
- Primo, S
- Jauch, K-W
- Nelson, P J
- Modest, D P
- Nieß, H
- Bruns, C
Producer: 20160411
In:
Zentralblatt fur Chirurgie vol. 140
Availability: No items available.
|
|
|
8.
|
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. [electronic resource] by
- Modest, D P
- Camaj, P
- Heinemann, V
- Schwarz, B
- Jung, A
- Laubender, R P
- Gamba, S
- Haertl, C
- Stintzing, S
- Primo, S
- Bruns, C J
Producer: 20130715
In:
Journal of cancer research and clinical oncology vol. 139
Availability: No items available.
|
|
|
9.
|
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. [electronic resource] by
- Modest, D P
- Jung, A
- Moosmann, N
- Laubender, R P
- Giessen, C
- Schulz, C
- Haas, M
- Neumann, J
- Boeck, S
- Kirchner, T
- Heinemann, V
- Stintzing, S
Producer: 20120831
In:
International journal of cancer vol. 131
Availability: No items available.
|
|
|
10.
|
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. [electronic resource] by
- Giessen, C
- Graeven, U
- Laubender, R P
- Modest, D P
- Schulz, C
- Porschen, R
- Schmiegel, W
- Reinacher-Schick, A
- Hegewisch-Becker, S
- Stintzing, S
- Heinemann, V
Producer: 20140707
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 24
Availability: No items available.
|
|
|
11.
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. [electronic resource] by
- Stintzing, S
- Fischer von Weikersthal, L
- Decker, T
- Vehling-Kaiser, U
- Jäger, E
- Heintges, T
- Stoll, C
- Giessen, C
- Modest, D P
- Neumann, J
- Jung, A
- Kirchner, T
- Scheithauer, W
- Heinemann, V
Producer: 20121022
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 23
Availability: No items available.
|
|
|
12.
|
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. [electronic resource] by
- Modest, D P
- Denecke, T
- Pratschke, J
- Ricard, I
- Lang, H
- Bemelmans, M
- Becker, T
- Rentsch, M
- Seehofer, D
- Bruns, C J
- Gebauer, B
- Modest, H I
- Held, S
- Folprecht, G
- Heinemann, V
- Neumann, U P
Producer: 20180813
In:
European journal of cancer (Oxford, England : 1990) vol. 88
Availability: No items available.
|
|
|
13.
|
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. [electronic resource] by
- Modest, D P
- Ricard, I
- Heinemann, V
- Hegewisch-Becker, S
- Schmiegel, W
- Porschen, R
- Stintzing, S
- Graeven, U
- Arnold, D
- von Weikersthal, L F
- Giessen-Jung, C
- Stahler, A
- Schmoll, H J
- Jung, A
- Kirchner, T
- Tannapfel, A
- Reinacher-Schick, A
Producer: 20180102
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 27
Availability: No items available.
|
|
|
14.
|
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). [electronic resource] by
- Stahler, A
- Heinemann, V
- Giessen-Jung, C
- Crispin, A
- Schalhorn, A
- Stintzing, S
- Fischer von Weikersthal, L
- Vehling-Kaiser, U
- Stauch, M
- Quietzsch, D
- Held, S
- von Einem, J C
- Holch, J
- Neumann, J
- Kirchner, T
- Jung, A
- Modest, D P
Producer: 20160601
In:
International journal of cancer vol. 138
Availability: No items available.
|
|
|
15.
|
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). [electronic resource] by
- Holch, J W
- Ricard, I
- Stintzing, S
- Fischer von Weikersthal, L
- Decker, T
- Kiani, A
- Vehling-Kaiser, U
- Heintges, T
- Kahl, C
- Kullmann, F
- Scheithauer, W
- Moehler, M
- Jelas, I
- Modest, D P
- Westphalen, C B
- von Einem, J C
- Michl, M
- Heinemann, V
Producer: 20200504
In:
European journal of cancer (Oxford, England : 1990) vol. 106
Availability: No items available.
|
|
|
16.
|
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. [electronic resource] by
- Stintzing, S
- Miller-Phillips, L
- Modest, D P
- Fischer von Weikersthal, L
- Decker, T
- Kiani, A
- Vehling-Kaiser, U
- Al-Batran, S-E
- Heintges, T
- Kahl, C
- Seipelt, G
- Kullmann, F
- Stauch, M
- Scheithauer, W
- Held, S
- Moehler, M
- Jagenburg, A
- Kirchner, T
- Jung, A
- Heinemann, V
Producer: 20170821
In:
European journal of cancer (Oxford, England : 1990) vol. 79
Availability: No items available.
|
|
|
17.
|
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. [electronic resource] by
- von Einem, J C
- Heinemann, V
- von Weikersthal, L Fischer
- Vehling-Kaiser, U
- Stauch, M
- Hass, H G
- Decker, T
- Klein, S
- Held, S
- Jung, A
- Kirchner, T
- Haas, M
- Holch, J
- Michl, M
- Aubele, P
- Boeck, S
- Schulz, C
- Giessen, C
- Stintzing, S
- Modest, D P
Producer: 20141103
In:
Journal of cancer research and clinical oncology vol. 140
Availability: No items available.
|
|
|
18.
|
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). [electronic resource] by
- Modest, D P
- Ricard, I
- Stintzing, S
- Fischer von Weikersthal, L
- Decker, T
- Kiani, A
- Vehling-Kaiser, U
- Al-Batran, S-E
- Heintges, T
- Kahl, C
- Seipelt, G
- Kullmann, F
- Scheithauer, W
- Moehler, M
- Westphalen, C B
- Holch, J W
- von Einem, J C
- Held, S
- Heinemann, V
Producer: 20171010
In:
European journal of cancer (Oxford, England : 1990) vol. 84
Availability: No items available.
|
|
|
19.
|
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. [electronic resource] by
- Stintzing, S
- Wirapati, P
- Lenz, H-J
- Neureiter, D
- Fischer von Weikersthal, L
- Decker, T
- Kiani, A
- Kaiser, F
- Al-Batran, S
- Heintges, T
- Lerchenmüller, C
- Kahl, C
- Seipelt, G
- Kullmann, F
- Moehler, M
- Scheithauer, W
- Held, S
- Modest, D P
- Jung, A
- Kirchner, T
- Aderka, D
- Tejpar, S
- Heinemann, V
Producer: 20200803
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 30
Availability: No items available.
|
|
|
20.
|
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). [electronic resource] by
- Michl, M
- Stintzing, S
- Fischer von Weikersthal, L
- Decker, T
- Kiani, A
- Vehling-Kaiser, U
- Al-Batran, S-E
- Heintges, T
- Lerchenmueller, C
- Kahl, C
- Seipelt, G
- Kullmann, F
- Stauch, M
- Scheithauer, W
- Hielscher, J
- Scholz, M
- Mueller, S
- Lerch, M M
- Modest, D P
- Kirchner, T
- Jung, A
- Heinemann, V
Producer: 20171226
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 27
Availability: No items available.
|